Aayush Wellness Limited Board of Directors approved the notice for its 42nd Annual General Meeting (AGM) and proposed key governance appointments on September 3, 2026.

The board meeting, held in Mumbai, focused on procedural matters for the upcoming shareholder vote scheduled for September 29, 2026. No financial results were declared during this session.

Governance Appointments

The board proposed the reappointment of Mr. Gavadu Patil as a Non-Executive Non-Independent Director. Mr. Patil retires by rotation at the ensuing AGM and has offered himself for reappointment. He brings over two decades of experience in business operations and technology.

Additionally, the company proposed appointing M/s. A. Raghavendra Rao & Associates as Statutory Auditors. The firm will serve for five consecutive years, from the conclusion of the 42nd AGM to the 47th AGM, subject to member approval.

AGM Logistics

The 42nd AGM will be conducted via Video Conferencing or Other Audio-Visual Means. Key dates for shareholders are outlined below:

M/s. Aarju Agrawal & Associates has been appointed as the Scrutinizer to ensure fair and transparent voting procedures.

Mumbai, August 29, 2026 — Aayush Wellness launched Lung Care Tablets on August 29, 2026, entering the ₹18,913 crore respiratory healthcare market. The product targets smokers and individuals with respiratory issues.

The company disclosed the launch under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Managing Director Naveenakumar Kunjaru stated the move aligns with the firm’s prevention-led vision, building on the success of Aayush Herbal Masala.

Market Context

India’s respiratory healthcare segment recorded sales of ₹18,912.64 crore in 2025, up from ₹17,199.40 crore in 2024. This represents approximately 10% year-on-year growth. The company noted that India accounts for 30.28% of global deaths from respiratory diseases.

Product Formulation

Lung Care Tablets combine herbal and nutritional ingredients, including N-Acetyl Cysteine (NAC), Vasaka Extract, Licorice, Quercetin, Vitamin C, Vitamin D2, and Zinc. The formulation aims to support:

• Respiratory wellness and lung function
• Healthy airway function
• Antioxidant and immune support
• Healthy inflammatory response
• Overall lung-health maintenance

What the Numbers Show

The 10% growth in the respiratory segment sales from ₹17,199.40 crore in 2024 to ₹18,912.64 crore in 2025 indicates consistent expansion in this therapeutic category. This growth trajectory supports the company’s strategic entry into a market where India holds a significant share of global disease burden.

Strategic Outlook

Aayush Wellness positions the new tablets as a daily wellness solution to complement its existing preventive-health products. The company aims to increase product depth and create cross-selling opportunities across its customer base by addressing rising health concerns with targeted solutions.